Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
03 11 2020
Historique:
entrez: 4 11 2020
pubmed: 5 11 2020
medline: 8 9 2021
Statut: epublish

Résumé

Protease inhibitors (PIs) are the second- and last-line therapy for the majority of HIV-infected patients worldwide. Only around 20% of individuals who fail PI regimens develop major resistance mutations in protease. We sought to explore the role of mutations in

Identifiants

pubmed: 33144375
pii: mBio.02036-20
doi: 10.1128/mBio.02036-20
pmc: PMC7642677
pii:
doi:

Substances chimiques

HIV Antigens 0
Protease Inhibitors 0
gag Gene Products, Human Immunodeficiency Virus 0
p17 protein, Human Immunodeficiency Virus Type 1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI147331
Pays : United States
Organisme : Medical Research Council
ID : MR/S023380/1
Pays : United Kingdom
Organisme : PEPFAR
Pays : United States
Organisme : Wellcome Trust
ID : WT108082AIA
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Datir et al.

Références

PLoS One. 2015 Sep 18;10(9):e0137834
pubmed: 26382239
Int J Antimicrob Agents. 2016 Aug;48(2):158-62
pubmed: 27345268
Retrovirology. 2012 Oct 23;9:87
pubmed: 23092122
Cell Host Microbe. 2019 Jul 10;26(1):48-60
pubmed: 31295424
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2248-56
pubmed: 26833162
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9040-9049
pubmed: 30975760
J Virol. 2019 Dec 12;94(1):
pubmed: 31619553
J Clin Invest. 2013 Sep;123(9):3848-60
pubmed: 23979165
PLoS One. 2013 Sep 17;8(9):e73582
pubmed: 24069209
J Med Chem. 2016 Jan 28;59(2):545-58
pubmed: 26685880
Lancet Infect Dis. 2009 Jul;9(7):409-17
pubmed: 19555900
AIDS. 2010 Jul 17;24(11):1651-5
pubmed: 20597164
Retrovirology. 2012 Aug 06;9:63
pubmed: 22867298
J Infect. 2007 Apr;54(4):367-74
pubmed: 16875739
Lancet. 2012 Oct 6;380(9849):1250-8
pubmed: 22828485
AIDS Res Hum Retroviruses. 2015 Oct;31(10):1032-7
pubmed: 26258548
J Virol. 1998 Sep;72(9):7632-7
pubmed: 9696866
PLoS Med. 2015 Apr 07;12(4):e1001810
pubmed: 25849352
Clin Infect Dis. 2015 Nov 1;61(9):1453-61
pubmed: 26157050
Clin Infect Dis. 2019 Mar 19;68(7):1184-1192
pubmed: 30060027
J Antimicrob Chemother. 2014 Dec;69(12):3340-8
pubmed: 25096075
Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9
pubmed: 19451297
Lancet Infect Dis. 2017 Mar;17(3):296-304
pubmed: 27914856
J Acquir Immune Defic Syndr. 2011 Apr;56(4):333-9
pubmed: 21239995
AIDS. 2012 May 15;26(8):929-38
pubmed: 22313953
J Virol. 2009 Sep;83(18):9094-101
pubmed: 19587031
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20889-94
pubmed: 19864625
AIDS Res Hum Retroviruses. 2012 Jan;28(1):54-75
pubmed: 21848364
Sci Rep. 2017 Sep 14;7(1):11559
pubmed: 28912582
J Infect Dis. 2004 Jun 1;189(11):1983-7
pubmed: 15143463
Lancet Infect Dis. 2018 Mar;18(3):346-355
pubmed: 29198909
J Biol Chem. 2002 Feb 22;277(8):5952-61
pubmed: 11741936
J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):325-329
pubmed: 30531296
J Virol. 2013 Jan;87(1):454-63
pubmed: 23097440
J Antimicrob Chemother. 2019 May 1;74(5):1402-1407
pubmed: 30726945
Molecules. 2019 Sep 06;24(18):
pubmed: 31489889
Clin Infect Dis. 2017 Apr 15;64(8):1006-1016
pubmed: 28329393
J Antimicrob Chemother. 2016 Nov;71(11):3228-3234
pubmed: 27402006
PLoS Pathog. 2009 Mar;5(3):e1000345
pubmed: 19300491
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14331-6
pubmed: 26578780
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3099-104
pubmed: 8610175
Viruses. 2010 Jul;2(7):1411-26
pubmed: 21994687
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12456-12461
pubmed: 27791180
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Lancet Infect Dis. 2016 May;16(5):565-575
pubmed: 26831472
PLoS Med. 2007 Jan;4(1):e36
pubmed: 17227139
J Int AIDS Soc. 2017 Nov;20(3):
pubmed: 29098809

Auteurs

Rawlings Datir (R)

University College London, London, United Kingdom.

Steven Kemp (S)

University College London, London, United Kingdom.

Kate El Bouzidi (K)

University College London, London, United Kingdom.

Petra Mlchocova (P)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

Richard Goldstein (R)

University College London, London, United Kingdom.

Judy Breuer (J)

University College London, London, United Kingdom.

Greg J Towers (GJ)

University College London, London, United Kingdom.

Clare Jolly (C)

University College London, London, United Kingdom.

Miguel E Quiñones-Mateu (ME)

Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.

Patrick S Dakum (PS)

Institute for Human Virology, Abuja, Nigeria.
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Nicaise Ndembi (N)

Institute for Human Virology, Abuja, Nigeria.
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Ravindra K Gupta (RK)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom Rkg20@cam.ac.uk.
Africa Health Research Institute, Durban, South Africa.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH